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Post-translational regulation of ZEB1 contributes
to TGFβ-mediated EMT
Roxsan Manshouri

Mentor: Don L. Gibbons, MD, PhD
Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related death in the United
States due in part to the affinity of tumors to metastasize. Understanding the process which
contributes to metastasis provides promise for the discovery of novel therapeutic targets.
Epithelial-to-mesenchymal transition (EMT) is a proposed model for the initiation of metastasis.
During EMT epithelial cells lose their cell adhesion properties and acquire a mesenchymal-like
phenotype, allowing tumor cells to migrate from their epithelial cell community and invade
remote locations. EMT is mediated by several signaling pathways, with transforming growth
factor-beta (TGF-β) receiving attention for its up-regulation in the metastatic tumor
microenvironment. TGF-β facilitates EMT through a variety of mechanisms but a prominent
feature of TGF-β induced EMT is the activation of the transcription factor zinc finger E-boxbinding homeobox 1 (Zeb1). Although Zeb1 has an established role in EMT the mechanism by
which Zeb1 is regulated has not been fully elucidated. Here we demonstrate that Zeb1
undergoes post-translational modification and that this modification contributes to protein
stability. We also expose novel Zeb1 interactions using the BioID method for proximitydependent labeling of proteins. These results lead us to hypothesize that by targeting factors
that mediate Zeb1 post-translational modification we may provide a therapeutic approach for
metastasis suppression in NSCLC.
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Chapter 1:
Introduction

1

Lung cancer
Lung cancer is the current leading cause of all cancer related death in the United States
[1]. There are two major types of lung cancer: non-small cell lung cancer (NSCLC) and small cell
lung cancer (SCLC). NSCLC constitutes approximately 85% of lung cancers and comprises of
three subtypes: squamous cell carcinoma, large cell carcinoma, and adenocarcinoma--the most
common histologic type [2]. Poor patient prognosis is primarily due to the affinity of tumors to
develop metastasis leading to advanced disease at the time of diagnosis. Nearly two-thirds of
lung cancer patients are diagnosed with late stage disease and of patients who undergo surgery
approximately half will develop recurrence with metastatic disease [2]. Despite ongoing
research, much of which has focused on understanding tumor emergence and eradication, the
mortality rate of lung cancer patients has changed very little, due in part to the incomplete
understanding of the metastatic process.
With the intention of studying the biologic processes driving lung cancer progression
and metastasis, several genetic mouse models have been generated which are capable of
developing lung adenocarcinoma. In particular, the KrasLA1p53R172HDG (KP) genetically
engineered mouse model was found to recapitulate features of metastasis-prone lung cancer
patients [3]. A panel of lung adenocarcinoma cell lines were derived from the KP model from
various primary and metastatic tumor sites and were subcutaneously injected into syngeneic
mice to confirm their propensity to metastasize [4]. The cell line 393P (derived from primary
lung tumor) was defined as a metastasis incompetent cell line, 344SQ (subcutaneous
metastasis) was a metastasis prone cell line, and 393LN (lymph node metastasis) was capable of
intermediate metastasis. This evaluation was based on 393LN ability to produce lung
2

metastases when injected by tail vein or intra-cardiac injection, but not subcutaneously, while
393P cells were not able to form lung metastases through either method [3].
Using 393P as a reference control, these three cell lines were transcriptionally profiled
to reveal differential gene expression between metastatic and non-metastatic tumors. The
genes associated with metal ion binding and zinc ion binding were found to be up-regulated in
the 344SQ tumor compared to the 393P tumor, whereas the genes categorized as tight
junction, cell differentiation, and multicellular organismal development were down-regulated.
Based on these characteristics it was determined that the 344SQ tumor profile was consistent
with cells undergoing the biological process epithelial-mesenchymal transition (EMT) [4].
Epithelial-mesenchymal transition
EMT is the mechanism by which epithelial cells lose their apical-basal polarity and
specialized cell contacts to acquire migratory behavior and mesenchymal-like phenotype [5].
EMT enables cells to detach from the epithelial cell layer from which they originate and invade
remote locations where they may then undergo mesenchymal-epithelial transition (MET), the
reversion to an epithelial phenotype. Several distinct molecular mechanisms are involved in
EMT including reorganization of the active cytoskeleton, activation of transcription factors,
increased resistance to apoptosis and production of ECM-degrading enzymes, as well as
changes in microRNA expression[6]. This process is integral to wound healing and embryonic
development; however, activation of EMT has also been proposed as the crucial mechanism for
the initiation of metastatic dissemination by epithelial cancer cells [6].
Induction of an EMT has been associated with the expression of numerous
mesenchymal markers such as vimentin and N-Cadherin. Once malignant cells have successfully
3

micro- and macro-metastasized these cells then undergo MET whereby they regain epithelial
markers such as E-Cadherin and Crb3 to facilitate secondary tumor colonization [6]. EMT is
induced by multiple signals originating from the tumor-associated stromal cells. Growth factors
such as HGF, EGF, PDGF, and TGF-β mediate EMT through regulation of the transcription factors
Snail, Slug, Twist, and most notably zinc finger E-box binding homeobox 1 (ZEB1). When
expressed, these transcription factors orchestrate EMT through the regulation of genes
associated with the epithelial phenotype [6].
Zinc finger E-box-binding homeobox 1
ZEB1 is a 124 kDa transcription factor which is characterized by two terminal flanking
zinc finger clusters allowing for binding to the E-box typically located in the promoter of the
target gene, as well as a centrally located homeobox domain (Fig. 1). Originally identified for its
role in cell differentiation and embryogenesis, the ability of ZEB1 to induce an EMT has defined
ZEB1 as an important factor in metastasis [7]. In fact, dysregulation of ZEB1 has been associated
with tumor progression in NSCLC and several other cancer types [8-10], thus understanding the
regulation and role of ZEB1 in EMT could provide a therapeutic approach to the control of
metastatic disease.
ZEB1 facilitates EMT through the regulation of several genes responsible for an
epithelial phenotype such as epithelial cell polarity genes, classical cadherins, desmosome
proteins, tight and gap junction proteins, apical and vesicle transport proteins, and epithelial
cell surface receptors [11]. In particular, ZEB1 direct transcriptional repression of E-Cadherin--a
central component in cell-cell adherens junction—in human cancer cell has established ZEB1 as
a master regulator of epithelial cell plasticity [12].
4
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ZEB1 involvement in a negative feedback loop with the miR-200 family members has
recently been described in various carcinomas [13]. The family consists of five members (miR200a, miR-200b, miR-200c, miR-141, and miR-429) located in two clusters: miR-200a, miR200b,
miR-429 and miR-200c, miR-141. ZEB1 directly represses the miR-200 family through direct
binding to the promoter regions thus forming a regulatory loop which is responsible for
maintain cells in an epithelial or mesenchymal phenotype. Conversely, ZEB1 is a target of the
miR-200 family [14]. Down-regulation of the miR-200 family in metastatic NSCLC cells has been
reported and has been shown to be necessary and sufficient to initiate EMT [4].
Although ZEB1 has a predicted molecular weight of 124 kDa several groups have
reported discrepancies in the observed molecular weight (approximately 225 kDa) [15]. The
interplay between ZEB1 and various co-repressors and co-activators regulate ZEB1 activity
under specific conditions through post-translational modification (PTM) [15-18]. In human
cholangiocarcinoma cell lines, HuCCT1, the histone acetyltransferases p300 and p/CAF was
revealed to acetylate ZEB1, resulting in release of ZEB1 transcriptional suppression of target
genes [17]. Additionally, in a radioresistant subpopulations of breast cancer cells it was found
that ATM phosphorylates and stabilizes ZEB1 in response to DNA damage, thereby promoting
DNA repair and radiation resistance [15]. Despite the dissimilarity between the predicted and
observed ZEB1 size, no group has been able to account for the total difference in molecular
weight. In particular, few have shown the role of PTMs in regulating ZEB1 function. Here we
show that ZEB1 is post-translationally modified in NSCLC and that this modification is essential
to TGF-β mediated EMT.

6

Chapter 2:
Materials and
Methods

7

Cell Culture
Human lung cancer cell lines H1155, H157, H441 and H358 were obtained from the
National Cancer Institute (NCI-H series) or the Hamon Center for Therapeutic Oncology
Research, University of Texas Southwestern Medical Center (HCC series). Cell lines from the
p53R172HΔg/+ K-rasLA1/+ mice were derived and maintained as previously described [4]. Cell line
names depict the mouse number and site of derivation (e.g., 393P was derived from primary
lung tumor). HEK/293 Flp-In T-Rex were provided by the Raught laboratory (University of
Toronto) and were cultured in DMEM with 0.4% Hygromycin B. All other cell lines were cultured
and passaged in RPMI 1640 supplemented with 10% fetal bovine serum (FBS) and incubated in
5% CO 2 at 37°C. The pTRIPZ-GFP [19] inducible cell lines as well as H157-Tripz-miR200ab were
cultured in full RPMI media with puromycin. Cells were incubated with recombinant human
TGF-β1 (Cell Signaling 8915LF) at 5 ng/mL.
RNA Interference
TRC Lentiviral pLKO.1 plasmid expressing scrambled control shRNA or murine ZEB1
shRNA (RHS4080) were purchased (ThermoScientific), containing the following ZEB1-specific
shRNAmir sequences: 5' - AAACCCAGGGCTGCCTTGGAAAAG - 3' (shRNA-mZEB1-1:
TRCN0000070819) and 5' - AAACCCAGGGCTGCCTTGGAAAAG - 3' (m-shRNA-mZEB1-3:
TRCN0000070822). 344SQ and 531LN2 cells were virally infected as previously described [20]
and cultured in RPMI 1640 with 10% FBS and puromycin.

8

Quantitative Real-Time PCR Analysis
Total RNA was extracted using TRIzol® Reagent (Life Technologies) and was isolated
according to the manufacturer's instructions. Analysis of mRNA levels was performed on a 7500
Fast Real-Time PCR System (Applied Biosystems) with SYBR® Green Real-Time PCR, using
primers designed using the NIH primer design tool. The ribosomal housekeeping gene L32 was
used as an internal control and data was analyzed with the 7500 Software v2.0.5 (Applied
Biosystems). Student’s t-test was performed for statistical significance.
qRT-PCR primer 5’ to 3’
ms L32
GGAGAAGGTTCAAGGGCCAG
ms L32: R
TGCTCCCATAACCGATGTTG
ms Zeb1: F ATGCTCGAACGCGCAGC
ms Zeb1: R AATCGGCGATCTTTGAGAGCT
ms CDH1: F CCTCTCAAGCTCGCGGATA
ms CDH1: R TCCAACGTGGTCACCTGGT
ms CDH2: F TCCAFAFFFATCAAAGCCTGGGAC
ms CDH2: R CCGCATCAATGGCAGTGACCGT
ms Vim: F
TCCAAGCCTGACCTCACTGC
ms Vim: R
TTCATACTGCTGGCGCACAT
hs L32: F
CCTTGTGAAGCCCCAAGATCG
hs L32: R
TGCCGGATGAACTTCTTGGT
hs Zeb1: F
GGCATACACCTACTCAACTACGG
hs Zeb1: R
TGGGCGGTGTAGAATCAGAGTC
hs CDH1: F TTTACCCAGCCGGTCTTTGA
hs CDH1: R TCCTGGAACAGCGCCTTCT
Lambda Phosphatase incubation
Cells were lysed with 1 x NEBuffer for PMP supplemented with 1 mM MnCl2 or with 1 X RIPA
Buffer (Cell Signaling 9806). Lysates harvested in the PMP buffer (30 μg) was treated with 400
units of lambda-phosphatase/20 μL for 30 min. at 37 ͦ C. Samples were immediately separated
on an SDS polyacrylamide gel and transferred onto a nitrocellulose membrane.
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Immunoblot
Protein estimation was conducted by use of the Pierce™ BCA Protein Assay Kit (Thermo
Scientific, Cat. No. 23227). Samples were separated on SDS polyacrylamide gels and transferred
onto a nitrocellulose membrane. The membranes were blocked using 5% nonfat dry milk and
incubated in primary antibody overnight at 4oC (see Table 2 for antibody list). Membranes were
exposed using ECL (GE Healthcare) per the manufacturer’s instructions.
Gene
Zeb1
Zeb1
normal mouse IgG
normal rabbit IgG
E-Cadherin
Vimentin
Flag
GFP
B-actin
Phospho-(Ser/Thr) Phe
Phospho-Tyrosine,
Acetylated Lysine

Company
Santa Cruz
Cell Signaling
Santa Cruz
Santa Cruz
B&D
Cell Signaling
Sigma
Santa Cruz
Sigma
Cell Signaling
Cell Signaling
Cell Signaling

Catalog No.
H-102
3396
SC-2025
SC-2027
160182
3932
F1804
SC-9996
A1978
9631
9411
9441

Immunoprecipiation (IP)
Cell lines 393P-TG-Zeb1 and 393P-TG-Vec were cultured in 2 μg/ml doxycycline (dox) for 24 h to
induce GFP-Zeb1 production prior to lysis. Pull-down assays were performed using 500 μg of
crude lysate incubated overnight with 200 μg/ml anti-GFP (SC-9996) at 4 ͦ C and gentle
agitation. Protein A/G PLUS-Agarose Immunoprecipitation Reagent (SC-2003) was then
introduced for 2 hrs. Antibody-antigen complexes were washed with phosphate-buffered saline
(PBS) and Wash Buffer (50 mM Tris (pH 7.4), 150 mM NaCl, 1 mM EDTA, 1% Triton X-100),
eluted with 1 x RIPA buffer at 100 ͦC and separated by SDS-PAGE before Western blot analysis.
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Cycloheximide chase experiment
Wild type 393P and 344SQ cells were exposed to 100 μg/ml cycloheximide (C4859, SigmaAldrich) for up to 24 h. Samples were collected at the time points 0, 1, 2, 4, 8, and 24 h.
Western blot was then performed as described and quantification of immunoblot of ZEB1 was
conducted using densitometry software, Image Processing and Analysis in Java (ImageJ, NIH).
Half-life was calculated by:
T1/2= (elapsed time x log 2)/ log (beginning amount/ending amount)
3D culture
Cells were grown in 3D culture on 1.2 mg/ml Matrigel/Collagen Type I (Rat tail, Corning,
Product #354236) in eight-well glass chamber slides, as described (Sodunke TR et. al., 2007). A
single-cell suspension containing 1500 cells was plated onto a layer of Matrigel/Collagen (BD
Biosciences). The cells were grown in RPMI 1640 with 10% FBS and 2% Matrigel. Designated
samples were incubated with 5 ng/mL TGF-β. Cell growth and morphology were followed by
phase contrast microscopy on an Olympus IX 71 microscope.
Migration and Invasion Assay
Cells were resuspended in serum-free media and seeded in a 24-well Transwell or Matrigel
plate (BD Biosciences, pore size 8 μm) at a concentration of 5 x 104 per well. RPMI
supplemented with 10% FBS was added to the lower chamber and cells were allowed to
migrate for 16 h in 5% CO 2 at 37°C. Migrating cells were stained with 0.1% crystal violet. Nonmigrating cells were removed using a cotton swab. Migrated cells were quantified based on five
microscopic fields at a 4X magnification and results were represented as mean ± standard
11

deviation and student’s t-test was performed for statistical significance. Each assay was
performed in triplicate.
BioID system
Zeb1 was cloned from the pLenti-GIII-CMV-hZEB1-GFP-2A-Puro lentiviral vector (Applied
Biological Materials Inc., LV362466, Accession No. BC112392) using PCR amplified with primers
containing AscI and Not1 (N-terminus tag) or Kpn1 and NotI (C-terminus tag) restriction enzyme
sites and cloned in to the pcDNA5 FRT/TO FLAG-BirAR118G (pcDNA5 Flag-BirA*)[21] vectors
provided by Dr. Brian Raught (University of Toronto).
Primer name
Flag-BirA-[ZEB1] Asc1 -F
Flag-BirA-[ZEB1] NotI-R
[ZEB1]BirA-Flag KpnI -F
[ZEB1]BirA-Flag NotI-R

Sequence 5' to 3'
tataGGCGCGCCaATGgcggatggccccaggtg
ttaaGCGGCCGCaTCAggcttcatttgtctttt
tataGGTACCgccaccATGgcggatggccccaggtg
ttaaGCGGCCGCggtggcttcatttgtctttt

The N-terminus or C-terminus Flag-BirA tag vector control and Zeb1 were transfected into
HEK/293 Flp-In along with pOG44 Flp-Recombinase expression vector using Lipofectamine® LTX
Reagent with PLUS™ Reagent as per the manufacturer's instructions (Invitrogen, Cat. No.
15338100). Cell lines were cultured until colonies were ~3 mm in diameter at which point each
was trypsinized and divided into two pools. These were considered as a biological replicate and
were processed independently.
Subsequently, all cell lines were cultured in four different conditions and harvested:
(1) DMEM + 10% FBS.
(2) DMEM + 10% FBS + 5 μM MG-132
(3) DMEM + 10% FBS + 1 μg/ml Tetracyclin and 50 μM biotin
(4) DMEM + 10% FBS + 1 μg/ml Tetracyclin, 50 μM biotin, and 5 μM MG-132
12

Samples were snap-frozen and shipped on dry ice to the Raught laboratory for processing, mass
spectrometry, and analysis.
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Chapter 3:
Results
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Comparison of TGF-β and ZEB1 induced EMT
Our group has previously shown that the tumor microenvironment of metastasis prone
tumors (344SQ) have higher expression of TGF-β compared to metastasis incompetent tumors
(393P) [1]. In fact, 393P tumors require a greater time of TGF-β exposure to produce a
morphologic response (approximately 5-7 days) compared to 344SQ cells, which undergo an
EMT within 24 h, displaying a fibroblastic-like phenotype (Fig. 2A). When both cell lines are
cultured in a 3D assay in which a single cell suspension is plated on a thin Matrigel (MG) layer
393P cells grow as disorganized masses while 344SQ cells are capable of forming hollow, noninvasive epithelial spheres [4]. Upon TGF-β treatment these rounded structures are disrupted,
forming invasive protrusions and becoming highly proliferative (Fig. 2B).
Our work has also demonstrated constitutive Zeb1 expression to be sufficient in
inducing an invasive phenotype in 393P [22]. To fully characterize this phenotype and compare
the contribution of Zeb1 during TGF-β-mediated EMT, the cell lines 393P-TripZ-GFP-Zeb1 (393PGFP-Zeb1) and 344SQ-TripZ-GFP-Zeb1 (344SQ-GFP-Zeb1) were created, which have inducible
expression of a GFP-tagged ZEB1. In both cell lines a striking phenotypic EMT was observed
within 24 h of Zeb1 expression in 2D culture (Fig. 3A and 4A). EMT was also observed at the
protein and mRNA level (Fig. 3B, 4B and 4C). This phenotype was similar to 344SQ cells treated
with TGF-β (Fig. 2A). Correspondingly, when 344SQ cell lines were cultured in a modified 3D
assay, in which a Matrigel/collagen-type I (MG/ColI) mix is used to better mimic the tumor
microenvironment, the Zeb1 inducible cells which were dox induced upon plating were highly
invasive and produced spindle-like protrusions (Fig. 5B). However, when 344SQ-GFP-Zeb1 cells
were allowed to form spheres (7 days) prior to dox induction, spheres remained phenotypically
15
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non-invasive (Fig. 5C). Quantification of invasion reinforce the observed phenotype (Fig. 5D) as
well changes in the mRNA expression of ZEB1 and E-Cadherin (Fig. 5E). This suggests that Zeb1
is required for the invasive phenotype, but Zeb1 expression is not sufficient to overcome an
epithelial state.
Knockdown reveals the significance of Zeb1 expression during EMT
To determine the significance of ZEB1 in the initiation of EMT, shRNA-Zeb1 knockdowns
(KD) were generated using the 344SQ WT cells. KD was confirmed by qPCR, with 63.84%
reduction seen in 344SQ-shRNA-Zeb1#1 and 47.64% reduction in 344SQ-shRNA-Zeb1#3 (Fig.
6B). This prominent effect on Zeb1 mRNA did not translate to the overall protein expression.
The higher molecular weight ZEB1 (225 kDa-ZEB1) expression was affected approximately 20%
in either KD compared to the lowest molecular weight ZEB1 (125 kDa-ZEB1) which was reduced
nearly 70% (Fig. 6C). Despite these discrepancies Zeb1 KD produced a shift to a more epithelial
phenotype, as displayed by the decrease of invasive cell protrusions (Fig. 6A).
Next we sought to assess the response of the Zeb1 KD cells to TGF-β, to examine the
requirement for Zeb1 as a mediator of the TGF-β effect. In 2D assays, Zeb1 KD cells were
treated with TGF-β for 96 h. EMT was observed in both KDs as compared to the phenotype (Fig.
7D) and EMT profile of the scramble (scr) by protein and mRNA (Fig. 7A, 7B and 7C) as well as
by functional assays. Migration and invasion of KD cell lines were significantly increased by the
addition of TGF-β to growth media (Fig. 8A and 8B). Dissimilarities were observed between the
two species of ZEB1. Although ZEB1 expression did not significantly change in the scr cell line
under TGF-β incubation, the 125 kDa-ZEB1 increased in both KD cell lines, while the 225 kDa-
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ZEB1 was reduced (Fig. 7B). This indicates that upon TGF-β mediated EMT, 225 kDa-ZEB1 has a
higher turnover and may contribute to the ZEB1 associated phenotype observed during EMT.
In order to better define whether Zeb1 knockdowns were capable of responding to TGFβ, knockdowns were grown in 3D MG/Col I and treated with TGF-β (Fig 8A). Once spheres
formed (day 7), samples were treated with 5 ng/ml TGF-β for an additional 4 days. Notably,
neither the scr nor the KD spheres formed a proper lumen. Similar to the response found in 2D
culture, in 3D cultures Zeb1 knockdowns were still responsive to TGF-β, as assessed by changes
to EMT markers at the mRNA level (Fig. 8D). All cell lines were hyper-proliferative as typically
observed with TGF-β. These results suggest that ZEB1 is a redundant factor in metastasis and
may not be required for TGF-β induced EMT, however further investigation must be conducted
to confirm this conclusion.
Immunoprecipitation of GFP-tagged ZEB1
Given evidence that the higher molecular weight ZEB1 contributes to TGF-β mediated
EMT and literature attributing this molecular weight difference to PTMs we sought to confirm
and define the PTMs responsible for ZEB1 function. Potential Zeb1 PTMs were assessed by use
of the 393P cell line expressing inducible GFP-tagged ZEB1 (393P-GFP-Zeb1) or control GFP
(393P-GFP). After dox induction for 24 h, the GFP-ZEB1 or GFP production were confirmed by
fluorescent imaging. ZEB1 was found localized to the nucleus in contrast to the vector control
which produced GFP throughout the cell. 393P-TG-Zeb1 cells displayed a scattered,
mesenchymal-like phenotype in 2D culture after 24 h (Fig. 2A). Whole cell lysates were then
harvested from 393P-GFP-Zeb1 and 393P-GFP prior to ZEB1 immunoprecipitation (IP) using an
anti-GFP antibody. The resulting protein was then separated by gel electrophoresis. As
23
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expected, the GFP-ZEB1 fusion protein (250 kDa) appeared at approximately 25 kDa larger than
the highest molecular weight form of ZEB1 (225 kDa) when probed by ZEB1 or GFP (Fig. 3B).
To determine specific ZEB1 PTMs, GFP-IP was performed with the 393P-GFP-Zeb1 whole
cell lysate followed by immunoblotting with various anti-PTM antibodies. Since phosphorylation
is one of the most common PTMs contributing to protein regulation, we initially
immunoblotted for phospho-Serine/Threonine and phospho-Tyrosine. No signal was detected
corresponding to the molecular weight of ZEB1 after IP for GFP (Fig. 9B). This result suggested
that ZEB1 is not phosphorylated. Lambda phosphatase (lambda PP) incubation was then
performed to confirm this result. Both murine (393P and 344SQ) and human (H441, H358,
H1299, and H157) NSCLC cell lines were harvested in either PMP buffer and incubated with
lambda PP or in RIPA buffer containing phosphatase inhibitors as a control. Western blot was
then performed using the phospho-Ser/Thr antibody to determine whether the treatment was
effective and indeed no phospho-Ser/Thr signal remained after treatment (lower panel of Fig.
10A & 10B). The same blots were then stripped and probed with the anti-ZEB1 antibody. The
signal was reduced in the samples which were harvested in PMP buffer alone when compared
to the RIPA buffer, however, the molecular weight of ZEB1 was not affected by the PMP buffer
lysis in the cell lines 393P, 344SQ, H157 and H1155. In these samples incubation with
phosphatase produced a significant ZEB1 molecular weight difference as compared to samples
harvested in PMP buffer alone, suggesting that ZEB1 is in fact phosphorylated (upper panel of
Fig. 10A & 10B). Interestingly, there was approximately 10 kDa difference in the ZEB1 molecular
weight between samples lysed in PMP buffer alone (Fig. 10A, lane 2 and lane 5) compared to
those incubated in lambda PP (Fig. 10A, lane 3 and lane 6) in the murine cell lines while there
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was 20 kDa difference in the human NSCLC cell lines (Fig. 10B lanes 8 and lane 11 compared to
lane 9 and lane 12). This may be due to differential phosphorylation in murine versus human
ZEB1.
We next wanted to address if ZEB1 is acetylated as previously described [17]. In
addition, we wanted to address whether the IP conditions or the antibodies were responsible
for the inconsistent phosphorylation results. The cell line H157 which has high expression of
ZEB1 was used to IP for endogenous ZEB1 followed by immunoblotting with an acetylatedlysine antibody (Fig. 11A). Notably, nothing was seen by western blot in the input (whole cell
lysate) lane leading us to conclude that this antibody is not useful for analysis of ZEB1
acetylation. The inverse experiment was also conducted in which the anti-acetylated-lysine
antibody was used to IP all acetylated proteins found in the whole cell lysate followed by
immunoblot with ZEB1 antibody (Fig. 11B). No signal corresponding to ZEB1 was observed by
either method suggesting that ZEB1 is not acetylated or that the lysis conditions are not
suitable for ZEB1 IP.
Post-translational modification prolongs the half-life of ZEB1 protein
PTMs frequently play a role in the function of cellular proteins by affecting protein
stability. To assess the role of PTMs on ZEB1 stability, a cycloheximide chase experiment was
conducted. Cycloheximide (CHX) inhibits protein biosynthesis by arresting DNA translation
through binding of the 60S ribosomal unit, allowing the decay rate of a protein of interest toZEB1- to be observed over time. A time course was conducted by treatment of the wild-type
cell lines 393P and 344SQ with 100 μg/ml CHX for up to 24 h. Immunoblot of the time course
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experiment reflected a differential decay rate between the two observed molecular weights of
ZEB1 in both cell lines (Fig 12A & 12B). Densitometry was performed using ImageJ software to
quantify the half-life of both observed ZEB1 molecular weights. The half-life of the 225 kDaZEB1 was 30.16 h while the 125 kDa-ZEB1 was 16.15 h (Fig 12B) in 393P cells and in 344SQ cells
the half-life was 108.62 h for 225-kDa ZEB1 and 70.83 h for 125 kDa-ZEB1 (Fig. 12A).
A similar experiment was conducted with the human NSCLC cell line H157 expressing
both miR200a and miR200b upon dox induction (H157- miR200ab) [23]. The miR200 family is
involved in a negative feedback loop with Zeb1 and is down-regulated in invasive cells. Dox
induction of the H157 cells was conducted in a similar manner to the CHX time course
experiment for 48 hours. Immunoblot revealed that again upon translational repression the
expression of the lowest molecular weight ZEB1 was affected more the higher molecular weight
ZEB1 (Fig. 12C). Densitometry was conducted using ImageJ software to quantify the half-life of
both observed ZEB1 molecular weights. After 48 h of miR200ab induction there was
approximately 99% reduction of the lowest molecular weight ZEB1 while the highest molecular
weight was not as prominently affected (reduced 59.02%). This data indicates that PTMs
increase ZEB1 protein stability and prolong protein half-life.
BioID method can define the ZEB1 protein interactome
After complications with the IP procedure and inability to identify specific regulators of
ZEB1 we decided to use the BioID method to determine protein interactions that may be
responsible for ZEB1 modification. BioID allows for biotinylation of proteins that interact with a
protein of interest fused to a mutated biotin ligase, BirA* [21]. These proximal proteins may
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then be affinity captured and identified by mass spectrometry. Rather than using an affinity
purification-based approach to identify proteins in a stable complex, the generation of the
BirA*-ZEB1 fusion protein allows for identification of proteins which may act transiently or be
involved in less stable interactions with ZEB1.
The human Zeb1 cDNA was cloned into the previously described pcDNA5-FlagBirAFRT/TO vector with the Flag-BirA* tag located at the N- or C- terminus (see Fig. 13A & 14A). The
Flag-BirA* vector and Zeb1 coding sequences were transfected into 293 T-Rex cells and cell
pools with inducible tetracycline (tet) protein expression were selected. Both versions of the
Flag-BirA*-Zeb1 fusion protein retained their biological activity as judged by repression of the
target gene E-Cadherin by Western analysis (fig. 13B & 14B) and by qRT-PCR (Fig. 13C & 14C).
The Flag-BirA* proteins alone were considered to be biologically inactive in all of these assays.
ZEB1 interactors will be identified from HEK/293 Flp-In cells grown under tet induction
for 24h, along with the proteasomal inhibitor MG-132. As of now we are awaiting the results
from the mass spectrometry analysis to differentiate between stable (Fig. 15A) and transient
interactions (Fig. 15B).
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Chapter 4:
Discussion
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Discussion
Metastasis is a multi-step process in which cellular changes facilitate the loss of cell-cell
contact enabling the primary tumor cells to invade distant sites. EMT is a proposed model for
the initiation of tumor metastasis. During EMT epithelial cells gain a mesenchymal-like
phenotype, promoting cell migration and subsequent invasion. The transcription factor ZEB1 is
a well-established facilitator of EMT through the regulation of genes such as E-Cadherin, which
are responsible for specialized cell contact. Zeb1 has been shown to be up-regulated in
metastatic lung cancer [24] and recent research has shown Zeb1 depletion can overcome
radiation and chemotherapy resistance [15, 25]; thus finding ZEB1-targeting agents has the
potential to eradicate highly invasive tumors. Despite research on the role of Zeb1 as a
regulator of EMT [13], a complete knowledge of ZEB1 interactors and their contribution to EMT
have yet to be defined. Regulation of ZEB1 expression through PTMs has been established by
several groups, however the role of PTMs in regulating ZEB1 function during EMT have not
been fully elucidated. Our study sought to uncover novel interactions which may facilitate PTM
of ZEB1 and to better understand the role of these PTMs on ZEB1 function in NSCLC.
In human bile duct carcinoma ZEB1 was shown to be lysine-acetylated by the cofactors
P300 and PCAF causing ZEB1 functional inhibition [17]. Our study was not able to duplicate
these experiments in NSCLC cell lines. Instead, our findings indicate that ZEB1 is most likely
heavily phosphorylated as determined by the lambda PP experiment (Fig. 10A & 10B). Although
no signal was found for a phosphorylated protein in the GFP-Zeb1 IP experiment (Fig. 9B), this
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conflicting result may be due to the harsh lysis and washing conditions inhibiting Western blot
antibody signal. Further experimentation must be conducted to validate these findings.
Considering that phosphorylation status is known to be important for protein-protein
interactions (PPI) and protein stability, turnover experiments were performed using both
murine and human cells. Previously, Zhang et al. researched the turnover of ZEB1 in radiation
resistant subpopulations of breast cancer cells [15]. The investigators concluded that ZEB1 halflife was increased by phosphorylation, however the actual calculated half-life estimate was not
provided. We disclosed the half-life of the endogenous ZEB1 in both murine cell lines through
the use of protein synthesis inhibitors and for the human H157 cell line by use of an inducible
miR-200ab model. We were also able to distinguish a differential effect between the two
species of ZEB1 (Fig. 12A and 12B). The mechanisms underlying these intriguing findings remain
unclear; nonetheless, the data suggests the importance of PTMs to ZEB1 protein stability.
While this study was in progress, Zhang et. al. reported that ZEB1 is a substrate of the
kinase ATM in a radiation resistant breast cancer cell line and to isolated ZEB1-interacting
proteins by Tandem affinity purification-mass spectrometry (TAP-MS analysis) [15]. In contrast
to our study, this research focused on proteins with stable interactions with ZEB1, which could
be identified through affinity purification. This methodology would not be expected to uncover
transient protein interactions. The BioID system recently was shown to overcome this obstacle
in identifying PPIs and to present a comprehensive, high confidence interactome comparable to
in vivo biological interactions [26]. In this study, two constructs were created, with the BirA*
ligase fused to the C- or N- terminus (Fig. 13A & 14A). One of the two inducible BioID cell lines
exhibited high expression in response to Dox induction (N-terminus tag; Fig. 14C), which will
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allow us to compare between biological scenarios in which ZEB1 is expressed at low basal levels
(such as in non-metastatic primary tumors) or high basal levels (metastatic tumors). Our next
approach in this project will be to distinguish stable and transient interactions and to confirm
the PPI in our murine model systems and potentially in human NSCLC patient samples.
Although the overexpression of ZEB1 in stable lines of 393P cells promotes cell invasion
together with the loss of adherens junctions [22], inducible expression of ZEB1 was not
sufficient to induce invasion in established 344SQ epithelial structures as determined by 3D
assays (Fig. 5D). This suggested that Zeb1 is required for the invasive phenotype, as previously
described; however Zeb1 expression is not sufficient to disassociate the pre-established
epithelial state typically observed in early stage disease. In contrast, the use of TGF-β in the
344SQ-shRNA-Zeb1 cells was still able to facilitate an EMT, providing evidence that ZEB1 may
not be required for the initiation of metastasis but instead may be responsible for the invasive
phenotype seen in metastatic tumors. Arguably, the nearly 40% remaining mRNA ZEB1
expression may have contributed to the capacity of the KD cells to initiate EMT. Further in vivo
experimentation using the 393P-GFP-Zeb1 cell line must be conducted to validate this
conclusion.
Interestingly, there was again a discrepancy noted between the two species of ZEB1 in
the 344SQ-shRNA-Zeb1 cell lines. The prominent effect of the Zeb1-shRNA on Zeb1 mRNA in
both KD cell lines did not translate to the overall protein expression. This discrepancy promotes
the hypothesis that PTMs modulate the protein half-life as the 125 kDa-Zeb1 was affected by
KD, while 225 kDa-Zeb1 was not. Upon TGF-β treatment the 225 kDa-ZEB1 was reduced by
treatment while the lower molecular weight was increased. This indicates that during TGF-β
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mediated EMT the 225 kDa-ZEB1 has a higher turnover and also that PTMs are required for
ZEB1 function in facilitating the invasive phenotype.
In conclusion, we confirm that ZEB1 has multiple PTMS, one of which is
phosphorylation. We demonstrate that these PTMs contribute to ZEB1 protein stability and
function. We also disclose that although ZEB1 expression promotes the invasive phenotype
seen in metastatic tumor, ZEB1 may not be the primary cause of loss of epithelial polarity, one
of the earliest signs of malignancy. Additional research must be performed to confirm this
observation. Furthermore, this data together with those implicating ZEB1 in therapeutic
resistance underscore the importance of defining ZEB1 interactors and highlights the suitability
of these interactors as therapeutic targets.
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